Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, with particular emphasis on pediatric endocrinology and other rare endocrine and metabolic disorders. Its 2025 press releases highlight a growing portfolio of eight commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, along with late-stage candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector.
The ETON news feed features updates on FDA regulatory milestones, product launches, financial results, and corporate developments. Examples include the U.S. FDA approval of KHINDIVI (hydrocortisone) Oral Solution for pediatric adrenocortical insufficiency, the FDA’s acceptance of the New Drug Application for ET-600 (desmopressin oral solution) with a specified PDUFA target action date, and quarterly earnings reports detailing product sales growth and pipeline investment. The company also reports on its acquisition and relaunch of INCRELEX and GALZIN, and on its inclusion in the Russell 2000 and Russell 3000 indexes.
Investors following ETON news can track how Eton’s commercial portfolio and pipeline evolve through regulatory decisions, label expansion efforts, clinical study plans, and conference participation. Regular press releases also discuss non-GAAP metrics such as Adjusted EBITDA, providing additional context for financial performance. This news page aggregates these company-issued updates so readers can review Eton’s rare disease strategy, key product milestones, and ongoing engagement with the healthcare and investment communities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eton Pharmaceuticals reported Q4 2022 revenue of $8.5 million, a 39% increase from $6.1 million a year earlier. Product sales and royalty revenue surged 220% year-over-year. Net income for the quarter was $0.9 million, down slightly from $1.0 million in Q4 2021. The company experienced eighth consecutive quarters of revenue growth, primarily driven by ALKINDI SPRINKLE and Carglumic Acid. Eton has also expanded its sales force to further boost growth and plans to launch Betaine soon. Upcoming milestones include an NDA filing for a rare disease candidate, ET-600, in Q2 2024, and preparing for dehydrated alcohol injection launch.